David Novak

Item: David Novak
Rating: 0.63
Author: StockAnalysis.com

Stock Analyst at Raymond James

(0.63)

# 4,113

Out of 5,111 analysts

Total ratings

42.86%

Success rate

-13.85%

Average return

Main Sectors:

Top Industries:

Stocks Rated by David Novak

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	ZYME Zymeworks	Downgrades: Outperform	$74	$25.48	+190.42%	6	Dec 10, 2021
	CBIO Crescent Biopharma	Maintains: Outperform	$300 → $270	$14.09	+1,816.25%	1	Feb 4, 2021

Zymeworks

Dec 10, 2021

Downgrades: Outperform

Price Target: $74

Current: $25.48

Upside: +190.42%

Crescent Biopharma

Feb 4, 2021

Maintains: Outperform

Price Target: $300 → $270

Current: $14.09

Upside: +1,816.25%